Health biotech leans earlier-stage with closer academic ties

Health biotech projects sit at lower technology-readiness levels, collaborate more with universities, and draw a larger share of Pillar I (Excellent Science) and Pillar III (Innovative Europe) EU Horizon funding (2015–2025) than non-health biotech.